MedTrace Logo

LILRB4 STAR-T Cells in the Treatment of R/R AML/CMML

NCT05548088 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2025-03-05

No results posted yet for this study

Summary

This study is an exploratory study to evaluate the safety, tolerability, and efficacy of LILRB4 STAR-T cells in relapsed and refractory acute myeloid leukemia/Chronic Granulocytic-Mononocytic Leukemia subjects.

Conditions

  • Relapsed/Refractory Acute Myeloid Leukemia and Chronic Granulocytic-Mononocytic Leukemia

Interventions

BIOLOGICAL

LILRB4 STAR-T cells

Subjects with relapsed/refractory acute myeloid leukemia will be enrolled in the study, and Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4and-3followed by infusion of STAR-T cells. STAR-T cells will be intravenously infused with a escalated dose of 1E6,3E6,6E6,1E7 cells/kg

Sponsors & Collaborators

  • Bristar Immunotech Limited

    collaborator UNKNOWN

  • Peking University People's Hospital

    lead OTHER

Principal Investigators

  • Xiangyu Zhao · PEKING UNICERSITY PEOPLE'S HOSPITAL

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-25
Primary Completion
2024-08-03
Completion
2024-08-03

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05548088 on ClinicalTrials.gov